Nima Farzan  . net worth and biography

Nima . Biography and Net Worth

Nima brings over two decades of executive leadership experience in the biopharma industry to our team. Prior to joining us, Nima spent seven years at PaxVax, where he was most recently President and CEO. While there, he successfully led a team of 250 people through a number of commercial product launches and negotiated the sale of PaxVax to Emergent BioSolutions in 2018. Prior to PaxVax, he was at Novartis AG in a series of roles of increasing responsibility, most recently as Vice President of US Marketing at Novartis’ Vaccines and Diagnostics division. Prior to Novartis, Nima worked at DoubleTwist, a pioneering genomics company, and was a consultant with Boston Consulting Group. He was a member of the founding Board of the Coalition for Epidemic Preparedness Innovations (CEPI). He is on the Executive Committee of the Northern California Chapter of Young President’s Organization (YPO) and a Trustee at the Hamlin School. He is also a Director of Keros Therapeutics (NASDAQ: KROS). He holds a BA in Human Biology from Stanford University and an MBA from the Harvard Business School.

How old is Nima Farzan .?

Mr. . is currently 48 years old. Learn More on Nima Farzan .'s age.

How do I contact Nima Farzan .?

The corporate mailing address for Mr. . and other Kinnate Biopharma executives is , , . Kinnate Biopharma can also be reached via phone at 858-299-4699 and via email at [email protected]. Learn More on Nima Farzan .'s contact information.

Has Nima Farzan . been buying or selling shares of Kinnate Biopharma?

Nima Farzan . has not been actively trading shares of Kinnate Biopharma during the past quarter. Learn More on Nima Farzan .'s trading history.

Who are Kinnate Biopharma's active insiders?

Kinnate Biopharma's insider roster includes Nima . (Pres), Carl Gordon (Director), Neha Krishnamohan (CFO), and Mark Meltz (COO). Learn More on Kinnate Biopharma's active insiders.

Are insiders buying or selling shares of Kinnate Biopharma?

In the last year, Kinnate Biopharma insiders bought shares 4 times. They purchased a total of 3,326,815 shares worth more than $9,074,491.04. The most recent insider tranaction occured on May, 8th when Director James B Tananbaum bought 1,780,000 shares worth more than $4,984,000.00. Insiders at Kinnate Biopharma own 41.7% of the company. Learn More about insider trades at Kinnate Biopharma.

Information on this page was last updated on 5/8/2023.

Nima Farzan . Insider Trading History at Kinnate Biopharma

See Full Table

Nima Farzan . Buying and Selling Activity at Kinnate Biopharma

This chart shows Mr. Nima Farzan .'s buying and selling at Kinnate Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kinnate Biopharma Company Overview

Kinnate Biopharma logo
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Read More

Today's Range

Now: $2.65
Low: $2.64
High: $2.68

50 Day Range

MA: $2.60
Low: $2.43
High: $2.66

2 Week Range

Now: $2.65
Low: $1.04
High: $7.18

Volume

2,812,200 shs

Average Volume

418,678 shs

Market Capitalization

$125.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38